Exabis Library
Welcome to the e-CCO Library!
P504: Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with real-world ulcerative colitis: A GETAID multicentre cohort study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P504: Guselkumab, an IL-23p19 subunit–specific monoclonal antibody, binds CD64+ myeloid cells and potently neutralises IL-23 produced from the same cells
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P504: How acceptable is a ‘treat to target’ (T2T) approach to IBD patients in clinical remission?
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P504: Prospective analysis of micronutrient status and disease course in Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P504: Stability observations in tacrolimus suppositories
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P504: The variation of faecal calprotectin after 3 months of anti-TNF therapy is a predictor of sustained clinical remission in patients with Crohn's disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P505: Early therapeutic drug monitoring after induction therapy with infliximab: correlation with intestinal ultrasound
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P505: Efficacy of MMX-mesalamine monotherapy for maintenance of remission in ulcerative colitis patients after mucosal healing
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P505: Factors influencing outcomes from surgery for Crohn’s disease: A perspective from a district hospital
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P505: Real word long-term efficacy and safety of vedolizumab in managing ulcerative colitis versus crohn's disease: results from “long vedo” italian multicenter study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P505: Real-world short-term effectiveness of ustekinumab in Crohn’s disease: Results from the ENEIDA Registry
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P505: Smoking is associated with the development of adverse events of biological therapy in patients with Inflammatory Bowel Disease
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P505: The effect of using a question prompt list in outpatient clinic consultations in a Dutch inflammatory bowel disease population
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P506: Endoscopic and clinical outcomes of upadacitinib in patients with moderate to severe Crohn's disease by baseline disease severity
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P506: Incidence risk of colorectal cancer, non-melanoma skin cancers and non-Hodgkin lymphoma in Japanese patients with ulcerative colitis based on large-scale claims database
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P506: Psychological factors and quality of life in inflammatory bowel diseases patients: the Psycho study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P506: Rates of clinical remission among patients with Ulcerative Colitis from real-world clinical practice settings from Germany
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P506: Serum infliximab and antibodies to infliximab levels in Crohn’s disease and ulcerative colitis patients on long-term maintenance therapy
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM